These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 20519801)

  • 21. The role of capecitabine in first-line treatment for patients with metastatic breast cancer.
    Gelmon K; Chan A; Harbeck N
    Oncologist; 2006; 11 Suppl 1():42-51. PubMed ID: 16971739
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A GINECO randomized phase II trial of two capecitabine and weekly paclitaxel schedules in metastatic breast cancer.
    Lortholary A; Hardy-Bessard AC; Bachelot T; de Rauglaudre G; Alexandre J; Bourgeois H; Jaubert D; Paraiso D; Largillier R
    Breast Cancer Res Treat; 2012 Jan; 131(1):127-35. PubMed ID: 21947680
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Capecitabine with weekly paclitaxel for advanced breast cancer: a phase I dose-finding trial.
    Uhlmann C; Ballabeni P; Rijken N; Brauchli P; Mingrone W; Rauch D; Pestalozzi BC; Rochlitz C; Aebi S; ;
    Oncology; 2004; 67(2):117-22. PubMed ID: 15539915
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer.
    Stockler MR; Harvey VJ; Francis PA; Byrne MJ; Ackland SP; Fitzharris B; Van Hazel G; Wilcken NR; Grimison PS; Nowak AK; Gainford MC; Fong A; Paksec L; Sourjina T; Zannino D; Gebski V; Simes RJ; Forbes JF; Coates AS
    J Clin Oncol; 2011 Dec; 29(34):4498-504. PubMed ID: 22025143
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Capecitabine and paclitaxel combination chemotherapy for inoperable or recurrent breast cancer: a phase I dose-finding study by the Kinki Breast Cancer Study Group.
    Masuda N; Taguchi T; Nakayama T; Shiba E; Watatani M; Kurebayashi J; Takatsuka Y; Sakamoto J; Noguchi S;
    Cancer Chemother Pharmacol; 2008 May; 61(6):989-95. PubMed ID: 17641893
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antitumor activity of erlotinib in combination with capecitabine in human tumor xenograft models.
    Ouchi KF; Yanagisawa M; Sekiguchi F; Tanaka Y
    Cancer Chemother Pharmacol; 2006 May; 57(5):693-702. PubMed ID: 16362295
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dose-finding and pharmacokinetic study of an all-oral combination regimen of oral vinorelbine and capecitabine for patients with metastatic breast cancer.
    Nolè F; Catania C; Sanna G; Imadalou K; Munzone E; Adamoli L; Longerey B; Blanchot G; Goldhirsch A
    Ann Oncol; 2006 Feb; 17(2):322-9. PubMed ID: 16303864
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A phase I dose escalation study of a pharmacobiologically based scheduling of capecitabine and mitomycin C in patients with gastrointestinal malignancies.
    Bekaii-Saab T; Hill M; Campbell A; Kosuri K; Thomas J; Villalona-Calero M
    Cancer Chemother Pharmacol; 2010 Apr; 65(5):863-9. PubMed ID: 19657639
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women.
    Bajetta E; Procopio G; Celio L; Gattinoni L; Della Torre S; Mariani L; Catena L; Ricotta R; Longarini R; Zilembo N; Buzzoni R
    J Clin Oncol; 2005 Apr; 23(10):2155-61. PubMed ID: 15710946
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Results of a phase I trial of intravenous vinorelbine plus oral capecitabine as first-line chemotherapy of metastatic breast cancer.
    Favier L; Isambert N; Zanetta S; Ferrant E; Mayer F; Chauffert B; Fumoleau P; Garnier J; Biville F; Coudert B
    Breast; 2008 Feb; 17(1):36-41. PubMed ID: 17698359
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of low-dose metronomic chemotherapy with capecitabine in heavily pretreated patients with metastatic breast cancer.
    Fedele P; Marino A; Orlando L; Schiavone P; Nacci A; Sponziello F; Rizzo P; Calvani N; Mazzoni E; Cinefra M; Cinieri S
    Eur J Cancer; 2012 Jan; 48(1):24-9. PubMed ID: 21775129
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer.
    Oshaughnessy JA; Blum J; Moiseyenko V; Jones SE; Miles D; Bell D; Rosso R; Mauriac L; Osterwalder B; Burger HU; Laws S
    Ann Oncol; 2001 Sep; 12(9):1247-54. PubMed ID: 11697835
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Taxanes and capecitabine in combination: rationale and clinical results.
    Maher JF; Villalona-Calero MA
    Clin Breast Cancer; 2002 Jan; 2(4):287-93. PubMed ID: 11899360
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase II study of 4-weekly capecitabine monotherapy in advanced/metastatic breast cancer.
    Kusama M; Nomizu T; Aogi K; Yoshimoto M; Horikoshi N; Tabei T; Noguchi S; Miura S; Yoshimura N; Kimura M; Toyama K; Shin E
    Breast Cancer; 2010 Oct; 17(4):233-40. PubMed ID: 19633909
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dose scheduling--Herceptin.
    Leyland-Jones B
    Oncology; 2001; 61 Suppl 2():31-6. PubMed ID: 11694785
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multicenter phase II study of oral capecitabine (Xeloda(")) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy.
    Reichardt P; Von Minckwitz G; Thuss-Patience PC; Jonat W; Kölbl H; Jänicke F; Kieback DG; Kuhn W; Schindler AE; Mohrmann S; Kaufmann M; Lück HJ
    Ann Oncol; 2003 Aug; 14(8):1227-33. PubMed ID: 12881384
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase II trial of capecitabine and weekly paclitaxel as first-line therapy for metastatic breast cancer.
    Blum JL; Dees EC; Chacko A; Doane L; Ethirajan S; Hopkins J; McMahon R; Merten S; Negron A; Neubauer M; Ilegbodu D; Boehm KA; Asmar L; O'Shaughnessy JA
    J Clin Oncol; 2006 Sep; 24(27):4384-90. PubMed ID: 16926223
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Capecitabine: have we got the dose right?
    Midgley R; Kerr DJ
    Nat Clin Pract Oncol; 2009 Jan; 6(1):17-24. PubMed ID: 18936793
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Oral capecitabine therapy: experience and developments at the Milano Cancer Institute].
    Longo F; Mansueto G
    Tumori; 2004; 90(1):suppl 17-27. PubMed ID: 15143996
    [No Abstract]   [Full Text] [Related]  

  • 40. A phase I-II study of postoperative capecitabine-based chemoradiotherapy in gastric cancer.
    Jansen EP; Boot H; Saunders MP; Crosby TD; Dubbelman R; Bartelink H; Verheij M; Cats A
    Int J Radiat Oncol Biol Phys; 2007 Dec; 69(5):1424-8. PubMed ID: 17689023
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.